阿布昔替尼治疗慢性光化性皮炎1例

doi:10.35541/cjd.20240388

中华皮肤科杂志 ›› 2025, e20240388.doi: 10.35541/cjd.20240388

• 病例报告 • 上一篇

阿布昔替尼治疗慢性光化性皮炎1例

孙瑞萍孟慧娟林清霞罗增香

山东第二医科大学附属医院皮肤科，潍坊 261000

收稿日期:2024-07-22 修回日期:2024-10-18 发布日期:2025-02-08
通讯作者: 罗增香 E-mail:lzxxgp@163.com

A case of chronic actinic dermatitis treated with abrocitinib

Sun Ruiping, Meng Huijuan, Lin Qingxia, Luo Zengxiang

Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, Weifang 261000, Shandong, China

Received:2024-07-22 Revised:2024-10-18 Published:2025-02-08
Contact: Luo Zengxiang E-mail:lzxxgp@163.com

摘要/Abstract

摘要： 患者女，66岁，农民。因头面、躯干、四肢红斑、丘疹伴痒15年、加重半年于2023年12月22日就诊。患者15年前因日晒后颈部及双上肢出现散在红斑、丘疹，瘙痒明显……

孙瑞萍孟慧娟林清霞罗增香. 阿布昔替尼治疗慢性光化性皮炎1例[J]. 中华皮肤科杂志, 2025,e20240388. doi:10.35541/cjd.20240388

Sun Ruiping, Meng Huijuan, Lin Qingxia, Luo Zengxiang. A case of chronic actinic dermatitis treated with abrocitinib[J]. Chinese Journal of Dermatology,2025,e20240388. doi:10.35541/cjd.20240388

参考文献 6

［1］	中国研究型医院学会皮肤科学专业委员会, 中国医师协会皮肤科医师分会. 慢性光化性皮炎诊疗专家共识（2023版）［J］. 中华皮肤科杂志, 2023,56（12）:1096⁃1106. doi: 10.35541/cjd. 20230433.
［2］	Ko DY, Choi SH, Ha SM, et al. The clinical severity score of chronic actinic dermatitis correlates with in vivo photoallergic reactions and the immunologic parameters related to a shift towards Th2 immunity from the Th2/Th1 balanced status in patients with chronic actinic dermatitis［J］. Photodermatol Photoimmunol Photomed, 2016,32（4）:199⁃206. doi: 10.1111/phpp.12244.
［3］	Beck LA, Cork MJ, Amagai M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis［J］. JID Innov, 2022,2（5）:100131. doi: 10.1016/j.xjidi.2022.100131.
［4］	Wohlrab J, Stintzing D, Schultz L, et al. Influence of Janus kinase inhibitors on the neuronal activity as a proof⁃of⁃concept model for itch［J］. Skin Pharmacol Physiol, 2022,35（2）:94⁃101. doi: 10. 1159/000519669.
［5］	Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomised, double⁃blind, multicentre phase 3 trial［J］. Lancet, 2022,400（10348）:273⁃282. doi: 10.1016/S0140⁃6736（22）01199⁃0.
［6］	Ständer S, Kwatra SG, Silverberg JI, et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate⁃to⁃severe atopic dermatitis: subgroup analysis of the randomized phase Ⅲ JADE COMPARE Trial［J］. Am J Clin Dermatol, 2023,24（1）:97⁃107. doi: 10.1007/s40257⁃022⁃00738⁃4.

阿布昔替尼治疗慢性光化性皮炎1例

A case of chronic actinic dermatitis treated with abrocitinib

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 6

相关文章 0

Metrics

本文评价

推荐阅读 10